Pfizer's ELREXFIO beats standard regimens in Phase 3 myeloma study
Pfizer says ELREXFIO met its primary endpoint in the MagnetisMM-32 Phase 3 study, showing a statistically significant reduction in disease progression risk.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Pfizer announced topline results from the Phase 3 MagnetisMM-32 study of ELREXFIO (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma. At a pre-specified interim efficacy analysis, the trial met its primary endpoint of progression-free survival, assessed by blinded independent central review. The drug showed a statistically significant reduction in the risk of progression or death compared with one of three standard regimens chosen by investigators: EloPd, PVd or Kd.
According to the company, an estimated 68% of ELREXFIO patients were progression-free at 18 months. Grade 3 or higher infections occurred in 27.5% of patients versus 18.1% in the comparator group, and Grade 5 infections in 0.8% versus 1.6%. Pfizer plans to submit the data to global health authorities and present detailed results at a future medical meeting.
why it matters
For markets, this is mainly a clinical update affecting one company and a niche oncology segment. Overall survival data remain immature, and Pfizer says the safety profile matches the drug's known profile. Any effect on Pfizer shares will depend on future regulatory decisions and the drug's commercial potential.
tags
instruments
sources
- Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma — TradingView, 27 October 2026 at 10:45 UTC
- Pfizer’S ELREXFIO Outperforms Standard Regimens And Meets Primary Endpoint In Phase 3 Study In Relapsed Or Refractory Multiple Myeloma — Reuters, 27 October 2026 at 11:34 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗